Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study - Scorecard - MDSpire

Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study

  • By

  • Bernard Benichou

  • Rainard Fuhr

  • Elodie Vernadal

  • Sonia Valero

  • Blanche Tamarit

  • Veronica Ferrer

  • Gloria Gonzalez-Aseguinolaza

  • Anne Douar

  • Marc Froissart

  • Annelise Brossel

  • Simone Floettmann

  • Francesca Del Bene

  • Céline Bouquet

  • Jean-Philippe Combal

  • June 17, 2026

  • 0 min

Share

Clinical Scorecard: Correction: VTX-PID as an Innovative Recombinant Immunoglobulin G-Degrading Enzyme (IdeS) for Enhanced AAV-Based Gene Therapy in Subjects with Neutralizing Antibodies: Findings from the Phase I NAVIgATE First-in-Human Trial

At a Glance

CategoryDetail
ConditionNeutralizing Antibodies in Gene Therapy - specify implications for treatment outcomes.
Key Mechanisms
Target Population
Care Setting

Key Highlights

  • highlight

Guideline-Based Recommendations

Diagnosis

  • Consider including diagnostic criteria for neutralizing antibodies.

Management

  • Outline management strategies for patients with neutralizing antibodies.

Monitoring & Follow-up

  • Suggest monitoring protocols for patients receiving VTX-PID.

Risks

  • Identify potential risks associated with VTX-PID treatment.

Patient & Prescribing Data

Participants in the NAVIgATE study

Use of VTX-PID for AAV-based gene therapy

Clinical Best Practices

  • best_practice

Related Resources & Content

Original Source(s)

Correction: VTX-PID as a novel recombinant immunoglobulin G–degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study

  • by Bernard Benichou, Rainard Fuhr, Elodie Vernadal, Sonia Valero, Blanche Tamarit, Veronica Ferrer, Gloria Gonzalez-Aseguinolaza, Anne Douar, Marc Froissart, Annelise Brossel, Simone Floettmann, Francesca Del Bene, Céline Bouquet, Jean-Philippe Combal

  • June 17, 2026

Related Content

Clinical characteristics, risk factors, and outcome of Enterococcal bacteraemia: Assessment of the DENOVA score in a diverse patient cohort

Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season

TLR7/8 agonist 3M-052 formulated in micelles induces local type I IFN response and antiviral immunity in zebrafish larvae